IP Library Granted Patent US 10,098,906
Granted Patent B2
US 10,098,906 · App. 15/031,020 · Granted Oct 16, 2018

Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation

Inventor: Hans-Ake Fabricius (Berlin, DE)
Assignee: CELL RECEPTOR AG
A61K31/727A61K31/737C08B37/0021C08B37/0057C08B37/0063C08B37/0069C08B37/0078C08B37/0084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,906
App. No.
15/031,020
Granted
Oct 16, 2018
Kind
B2
Abstract

The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.

Claims (10)

1. A method of treating cancer in a subject in need thereof comprising administering a pharmaceutical composition comprising a soluble sulfated polysaccharide to said subject, wherein said soluble sulfated polysaccharide does not comprise the terminal pentasaccharide of Heparin and has a degree of sulfation of greater than or equal to 1, and wherein proliferation of cancerous cells in the subject is reduced by said soluble sulfated polysaccharide inhibiting a physical interaction between cancer cell surfaces and platelets.

2. The method according to claim 1 , wherein said subject is a human.

3. The method according to claim 1 , wherein the degree of sulfation of said polysaccharide is >1.2.

4. The method according to claim 1 , wherein the degree of sulfation of said polysaccharide is >1.4.

5. The method according to claim 1 , wherein the soluble sulfated polysaccharide exhibits an average molecular weight of about 5000 to about 12000 daltons.

6. The method according to claim 1 , wherein the soluble sulfated polysaccharide is pentosan polysulfate (PPS).

7. The method according to claim 1 , wherein the soluble sulfated polysaccharide is dextran sulfate (DXS).

8. The method according to claim 1 , wherein said soluble sulfated polysaccharide is a sulfated alginate.

9. The method according to claim 1 , wherein said soluble sulfated polysaccharide is a sulfated fucoidan.

10. The method according to claim 1 , wherein said soluble sulfated polysaccharide is locally administered in proximity to a tumor.

Assignments (2)
CHANGE OF NAME Recorded Feb 5, 2018
From: CELL RECEPTOR GMBH
To: CELL RECEPTOR AG
Reel/Frame 046052/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2016
From: FABRICIUS, HANS-AKE
To: CELL RECEPTOR GMBH
Reel/Frame 038684/0154 →
Priority Claims (1)
DE 10 2013 111 630 · Oct 22, 2013 · national
Continuity (1)
Related Publication 20160367589A1 · Dec 22, 2016